ARTIVA BIOTHERAPEUTICS (ARTV) Stock News

Artiva Biotherapeutics (Nasdaq: ARTV) prioritized refractory rheumatoid arthritis (RA) as the lead indication for AlloNK (AB-101) and announced that the U.S. FDA granted Fast Track Designation for AlloNK in refractory RA in combination with rituximab. The company reported >20 patients treated with AlloNK plus monoclonal antibody therapy at 1 billion and 4 billion cell doses across multiple autoimmune indications.

Emerging translational and safety data are expected in mid-November; clinical response data from >15 refractory RA patients are expected in 1H 2026. FDA interactions are planned in 1H 2026 to discuss a potential pivotal trial.

Artiva Biotherapeutics (NASDAQ:ARTV), a clinical-stage biotech company focused on cell therapies for autoimmune diseases and cancers, will participate in the Cantor Global Healthcare Conference 2025. The company's management will engage in a fireside chat on September 3, 2025, at 9:45 a.m. EDT.

The presentation will be accessible through a live webcast in the "Investors" section of Artivabio.com, with the replay available for 90 days after the event. Management will also be available for meetings with registered conference attendees.

Artiva Biotherapeutics (NASDAQ:ARTV) has reported significant progress in its clinical trials for AlloNK® therapy in autoimmune diseases during Q2 2025. The company has treated over a dozen patients across multiple sites, with the first patient receiving AlloNK + rituximab in their global Phase 2a basket trial for various autoimmune conditions.

The company ended Q2 2025 with $142.4 million in cash and investments, providing runway into Q2 2027. Financial results showed R&D expenses of $17.9 million and a net loss of $21.3 million. Artiva plans to present initial safety and translational data by year-end 2025, along with announcing their lead indication, followed by clinical response data in 1H2026.

ArrePath (NASDAQ:CTNM) has announced the successful completion of a new financing round led by Boehringer Ingelheim Venture Fund, with participation from existing investors Insight Partners, Innospark, Nor'easter Ventures, and new investor AB Magnitude. The funding, combined with non-dilutive awards from PACE and CARB-X, will support the advancement of their lead program AP-001 and expand their antimicrobial compound development.

Additionally, the company has appointed Dr. Diego Miralles as the new Chair of the Board of Directors. Dr. Miralles brings extensive biotech and pharmaceutical industry experience, having served as CEO of multiple companies including AZURNA Therapeutics, Laronde, and Vividion Therapeutics, and held senior positions at Johnson & Johnson.

Artiva Biotherapeutics (NASDAQ: ARTV), a clinical-stage biotech company focused on developing cell therapies for autoimmune diseases and cancers, announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management will engage in a fireside chat on June 4, 2025, at 9:20 a.m. EDT. The presentation will be accessible via live webcast through the company's investor relations website, with a replay available for 90 days afterward. Additionally, the management team will be available for meetings with registered conference attendees.

Artiva Biotherapeutics (NASDAQ: ARTV) announced promising longer-term Phase 1/2 data for AlloNK® in combination with rituximab for treating B-cell non-Hodgkin lymphoma (B-NHL). The treatment showed a 64% complete response rate (9/14 patients) in heavily pretreated patients naive to CAR-T therapy. The median duration of response has not been reached and extends beyond 19.4 months, comparable to approved auto-CAR-T therapies. The treatment demonstrated a well-tolerated safety profile with no reported cases of cytokine release syndrome (CRS), immune effector cell associated neurotoxicity syndrome (ICANS), or graft-versus-host disease. Common side effects were primarily hematologic, including neutropenia (84%), leukopenia (82%), and lymphopenia (71%). The results suggest potential applications for treating autoimmune diseases through enhanced B-cell depletion in outpatient community settings.

Artiva Biotherapeutics (NASDAQ: ARTV) reported its Q1 2025 financial results and business updates. The company announced IND clearance and initiation of a global basket trial exploring AlloNK® + rituximab in multiple autoimmune conditions, marking the first allogeneic cell therapy trial for rheumatoid arthritis and Sjögren's disease in the U.S. The company ended Q1 2025 with $166.0 million in cash, extending runway into Q2 2027.

Key financial metrics include R&D expenses of $17.1 million (up from $11.2M in Q1 2024), G&A expenses of $5.1 million (up from $3.6M), and a net loss of $20.3 million (increased from $14.0M). The company's B-NHL trial data showed promising results comparable to approved auto-CAR-T therapies. Initial safety and translational data are expected by year-end 2025, with clinical response data in the lead indication planned for 1H2026.

Artiva Biotherapeutics announced new data presentations for their AlloNK® cell therapy at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in New Orleans this May.

Key highlights:

• New longer-term Phase 1/2 data shows promising results for AlloNK® combined with rituximab in treating relapsed/refractory B-cell non-Hodgkin lymphoma
• Treatment demonstrated prolonged response duration, deep B-cell depletion, and well-tolerated safety profile
• Results support AlloNK's potential for treating B-cell driven diseases in community settings

Two poster presentations are scheduled:

• May 13: AlloNK® Cell Therapy ± Rituximab in Patients with Non-Hodgkin Lymphoma
• May 15: AlloNK manufacturing process scalability and consistency

The presentations highlight Artiva's progress in developing accessible cell therapies for autoimmune diseases and cancers. Abstracts are available on the ASGCT website, with poster copies to be shared on Artiva's website after the presentations.

Artiva Biotherapeutics (ARTV) has appointed Dr. Subhashis Banerjee as Chief Medical Officer, succeeding Dr. Thorsten Graef who will continue as a strategic advisor. Dr. Banerjee brings over 20 years of clinical development experience in autoimmune diseases, previously serving as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb and SVP of Clinical Development at VYNE Therapeutics.

The appointment strengthens Artiva's focus on developing their AlloNK® program for B-cell driven autoimmune diseases. Dr. Banerjee's expertise includes development of blockbuster therapies like Humira®, Taltz®, Orencia®, and Sotyktu®. The company has also expanded its development team with key appointments including David Moriarty as SVP of Clinical Operations, Benjamin Dewees as SVP of Regulatory Affairs, and Feng Xu as SVP of Biometrics.